Sahyadri Hospitals

Sector: Healthcare  |  HQ: Pune, Maharashtra, India  |  Founded: 1996  |  Employees: 5,000+

Listed as: Privately held  | 

Company overview

Sahyadri Hospitals is the largest chain of multi-speciality tertiary care hospitals in Maharashtra, founded by neurosurgeon Dr Charudutt Apte in 1996 with a single 35-bed facility in Pune's Karve Road. From those modest beginnings the group has grown to operate a network of hospitals across Pune, Nashik, Karad and Ahmednagar, with a combined bed strength of more than 1,300. The group is known for high-acuity work in neurology, neurosurgery, cardiac sciences, oncology, organ transplantation and emergency trauma care, and it counts one of the most active solid organ transplant programmes in western India. Once a clinician-led family business, Sahyadri attracted private equity capital from Everstone Group in 2012, then changed hands again in 2019 when the Ontario Teachers' Pension Plan bought a majority stake. In 2024 Manipal Health Enterprises announced the acquisition of Sahyadri from Ontario Teachers', a transaction that made Manipal the largest hospital chain by bed count in India. The series of ownership changes underscores both the strategic value of the group's western India footprint and the broader institutionalisation of Indian healthcare.

Competitive position

Sahyadri Hospitals is the dominant private hospital chain in Pune and a leading multi-speciality network in Maharashtra outside Mumbai. It competes with Ruby Hall Clinic, Jehangir Hospital, Deenanath Mangeshkar Hospital and Aditya Birla Memorial Hospital in Pune, and increasingly with national chains expanding into the city, including Manipal, Apollo and Fortis. In Nashik and Karad it operates in less competed markets and serves a wider catchment that extends into satellite towns. The group is positioned in the mid-premium tariff band, well below Apollo's Mumbai and Hyderabad flagship rates but above general nursing homes, and it has cultivated a clinician-led reputation in neurosciences and transplants that has historically attracted referrals from across western Maharashtra.

Key risks

Tariff pressure from government health schemes Clinical talent attrition to rival chains Capital intensity of equipment refresh cycles

Outlook

Sahyadri Hospitals traces its origins to 1996, when Dr Charudutt Apte, a Pune-based neurosurgeon, started a 35-bed facility on Karve Road to provide tertiary care that was then largely unavailable in the city outside of public teaching hospitals. Over the next decade the group added a second hospital at Deccan Gymkhana and progressively widened its clinical scope from neurosciences to cardiac care, oncology, gastroenterology, orthopaedics and critical care. The institutional phase of Sahyadri's story began in 2012, when private equity firm Everstone Capital bought a controlling stake from the founders, the first time a PE house had taken control of a tertiary care chain in western India outside Mumbai. Everstone professionalised the management, introduced corporate governance disciplines and added beds at Hadapsar and Bibwewadi. In 2019 Ontario Teachers' Pension Plan acquired the chain for a reported enterprise value of around ₹1,200 crore, recapitalising the group and funding incremental capacity addition. OTPP's strategy emphasised consolidation of the western Maharashtra catchment, with new units at Nagar Road and the acquisition of facilities in Nashik and Karad. By 2022 the chain operated eight hospitals with more than 900 beds. In August 2024 Manipal Health Enterprises announced the acquisition of Sahyadri Hospitals from Ontario Teachers' for an enterprise value reported in the press at around ₹2,500 crore. The transaction made Manipal the largest hospital chain by bed count in India, surpassing Apollo on consolidated bed strength, and gave it a strong Pune anchor to complement its Bengaluru, Delhi and Kolkata clusters. As part of Manipal post 2024, Sahyadri retains its brand and clinical leadership but shares procurement, IT and certain back-office functions with the parent. The service portfolio spans neurology and neurosurgery, cardiology and cardiac surgery, oncology including medical, surgical and radiation, nephrology and renal transplantation, orthopaedics and joint replacement, gastroenterology, liver transplantation, paediatrics and neonatology, emergency and trauma services, and a growing internal medicine and preventive health stream. The group has historically been known for high-volume neurosurgery, with thousands of complex cases performed annually, and for one of the more active solid organ transplant programmes in Maharashtra outside Mumbai. The physical footprint includes flagship units in Pune at Karve Road, Deccan, Hadapsar, Bibwewadi, Nagar Road, plus units in Nashik, Karad and Ahmednagar, with combined bed strength of roughly 1,300. The Hadapsar and Nagar Road units serve as the high-acuity hubs with full intensive care, cath lab and operating theatre complements. Sahyadri also operates satellite outpatient and diagnostic clinics across Pune and nearby tier-2 towns to feed referral volumes. Financially, the unlisted group does not publish detailed accounts, but trade press estimates place revenue in the range of ₹900 crore to ₹1,100 crore in FY24 with healthy double-digit EBITDA margins. Pricing in Pune remains a few percentage points below comparable Mumbai facilities, which has helped the group remain a destination for patients from Solapur, Kolhapur, Aurangabad and parts of Goa. Strategy from 2025 to 2030, as a Manipal subsidiary, is expected to focus on capacity expansion at existing campuses through additional towers and ICUs, deeper penetration of payer mix into corporate insurance and CGHS schemes, expansion of speciality programmes in cardiac surgery and oncology, and integration with Manipal's clinical research, training and digital health initiatives. The regulatory environment for private hospitals in Maharashtra is shaped by the Bombay Nursing Homes Registration Act, the Clinical Establishments Act in relevant states, NABH accreditation norms, Pre Conception and Pre Natal Diagnostic Techniques Act compliance, and the Transplantation of Human Organs Act for transplant programmes. Pricing for procedures under state employee schemes and Ayushman Bharat is determined by panel rates, and the group must balance scheme volumes against tariff economics. Risks include continued tariff pressure from PMJAY and state schemes, attrition of senior clinicians to competing chains and standalone hospitals, manpower shortages in specialist nursing and technician roles, capital intensity of equipment replacement cycles for imaging and cath lab installations, and integration execution risk as part of Manipal. Management has historically been clinician-led, with Dr Charudutt Apte and his family retaining clinical mentorship even after the change of ownership. The professional management team has been strengthened over successive PE cycles, and post Manipal acquisition the group operates under the broader Manipal leadership while preserving local clinical autonomy. ESG initiatives include biomedical waste management compliance, energy efficiency programmes across major campuses, free or subsidised care for economically weaker section patients under state norms, and community outreach camps in nearby tier-2 and tier-3 towns. Governance under Manipal ownership is structured around board oversight, internal audit, and standard committee-led decision making, with the chain expected to benefit from group-level shared services in compliance and digital health.

KAMRIT point of view

Building or competing with Sahyadri?

KAMRIT advises promoters, family offices, and global enterprises evaluating greenfield entry into the healthcare sector. Our Bankable DPR with Cost Model and ROI benchmarks your project economics against the listed-company cost structure of Sahyadri and peers. The Execution Partnership tier covers everything from incorporation through commissioning. A 20-minute scoping call with our partners is free.

View all 1 related project report → Book a scoping call

Related KAMRIT project reports

These reports use Sahyadri Hospitals in benchmarking and competitive analysis sections.

Disclaimer: This profile is compiled by KAMRIT Financial Services LLP for educational and benchmarking purposes only. It is not investment advice, a recommendation to buy or sell securities, or a solicitation. Stock data is provided by Yahoo Finance and may be delayed by up to 20 minutes. Company financial commentary draws on publicly available filings, exchange disclosures, and KAMRIT industry research. Readers should consult a SEBI-registered investment adviser before making investment decisions. KAMRIT is a financial services and compliance firm, not a SEBI-registered investment adviser.